R
Russell Esterline
Researcher at AstraZeneca
Publications - 19
Citations - 340
Russell Esterline is an academic researcher from AstraZeneca. The author has contributed to research in topics: Medicine & Dapagliflozin. The author has an hindex of 5, co-authored 9 publications receiving 111 citations.
Papers
More filters
Journal ArticleDOI
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Mikhail Kosiborod,Mikhail Kosiborod,Russell Esterline,Remo H.M. Furtado,Jan Oscarsson,Samvel B. Gasparyan,Gary G. Koch,Felipe Martinez,Omar Mukhtar,Subodh Verma,Subodh Verma,Vijay K. Chopra,Joan Buenconsejo,Anna Maria Langkilde,Philip Ambery,Fengming Tang,Kensey Gosch,Sheryl L. Windsor,Emily E Akin,Ronaldo V P Soares,Diogo D.F. Moia,Matthew Aboudara,Conrado R. Hoffmann Filho,Audes D. M. Feitosa,Alberto Fonseca,Vishnu Garla,Robert Gordon,Ali Javaheri,Cristiano P Jaeger,Paulo Leães,Michael E. Nassif,Michael Pursley,Fabio Serra Silveira,Weimar Kunz Sebba Barroso,José Roberto Lazcano Soto,Lilia Nigro Maia,Otavio Berwanger +36 more
TL;DR: The DARE-19 trial as discussed by the authors was a randomized, double-blind, placebo-controlled trial of patients hospitalised with COVID-19 and with at least one cardiometabolic risk factor (i.e., hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease).
Journal ArticleDOI
MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors; clinical benefits by restoration of normal diurnal metabolism?
TL;DR: It is proposed that the cardio-renal benefits demonstrated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) treatment in T2D partly may be explained by their ability to drive consistent, overnight periods of increased catabolism brought about by constant glucosuria.
Journal ArticleDOI
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Mikhail Kosiborod,Mikhail Kosiborod,Otavio Berwanger,Gary G. Koch,Felipe Martinez,Omar Mukhtar,Subodh Verma,Subodh Verma,Vijay K. Chopra,Ali Javaheri,Philip Ambery,Samvel B. Gasparyan,Joan Buenconsejo,C. David Sjöström,Anna Maria Langkilde,Jan Oscarsson,Russell Esterline +16 more
TL;DR: Dapagliflozin, a sodium‐glucose cotransporter‐2 inhibitor, has shown significant cardio‐ and renoprotective benefits in patients with type 2 diabetes, heart failure and chronic kidney disease, and may provide similar organ protection in high‐risk patients with COVID‐19.
Journal ArticleDOI
Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study.
Jonas Oldgren,Sanna Laurila,Axel Åkerblom,Aino Latva-Rasku,Eleni Rebelos,Henrik Isackson,Maria Saarenhovi,Olof Eriksson,Kerstin Heurling,Edvin Johansson,Ulrica Wilderäng,Cecilia Karlsson,Russell Esterline,Ele Ferrannini,Jan Oscarsson,Pirjo Nuutila +15 more
TL;DR: In this article, the early effects of dapaglifliflozin on myocardial function and metabolism in patients with type 2 diabetes without heart failure were explored, and it was shown that the drug had no effect on the external left ventricular (LV) work.
Journal ArticleDOI
Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.
Per Lundkvist,Maria J. Pereira,Prasad G. Kamble,Petros Katsogiannos,Anna Maria Langkilde,Russell Esterline,Eva Johnsson,Jan W. Eriksson +7 more
TL;DR: The degree of glucose lowering markedly contributed to regulation of glucagon and insulin secretion and to lipid mobilization during short-term SGLT2 inhibition.